Session » Vasculitis – ANCA-Associated Poster (0414–0436)

Date: Saturday, November 6, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0428

ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0432

Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months

8:30AM-10:30AM: Abstract Number: 0422

Cancer in Patients with ANCA-associated Vasculitis: Which Came First, the Chicken or the Egg?

8:30AM-10:30AM: Abstract Number: 0429

Causes and Characteristics of Death in ANCA-Associated Vasculitis – A Large, Real-Life, Contemporary Cohort Analysis

8:30AM-10:30AM: Abstract Number: 0431

Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study

8:30AM-10:30AM: Abstract Number: 0420

Development and Validation of a Simulation Model for Maintenance Treatment in ANCA-Associated Vasculitis

8:30AM-10:30AM: Abstract Number: 0425

Diagnostic Accuracy of Muscle MRI for Muscular Vasculitis in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Pilot Study

8:30AM-10:30AM: Abstract Number: 0414

Effect of Induction Therapies on Ear, Nose and Throat Involvement in Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: Results from a Multi-center Cohort Study

8:30AM-10:30AM: Abstract Number: 0427

Increased Risk of Severe Infections and Mortality in Patients with Newly Diagnosed Anti-neutrophil Cytoplasmic Antibody–associated Vasculitis: A Population-based Study

8:30AM-10:30AM: Abstract Number: 0424

Incremental Healthcare Costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Compared to Asthma: Retrospective Analysis of Commercial Claims Data in the United States (US)

8:30AM-10:30AM: Abstract Number: 0430

Interstitial Lung Disease in ANCA-Associated Vasculitis: Associated Factors and Outcomes

8:30AM-10:30AM: Abstract Number: 0418

Longitudinal Patterns of Renal Function in ANCA-Associated Vasculitis

8:30AM-10:30AM: Abstract Number: 0435

Myeloperoxidase Activity in Individuals with Antineutrophil Cytoplasmic Antibodies (ANCA) Can Be Inhibited by RLS-0071

8:30AM-10:30AM: Abstract Number: 0421

Negative vs. Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis, a Case-control Study

8:30AM-10:30AM: Abstract Number: 0417

Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study

8:30AM-10:30AM: Abstract Number: 0436

Ocular and Orbital Manifestations of Granulomatosis with Polyangiitis: A Systematic Review of Published Cases

8:30AM-10:30AM: Abstract Number: 0426

Ocular Manifestations of ANCA-Associated Vasculitis

8:30AM-10:30AM: Abstract Number: 0416

Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis

8:30AM-10:30AM: Abstract Number: 0419

Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study

8:30AM-10:30AM: Abstract Number: 0434

Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis

8:30AM-10:30AM: Abstract Number: 0423

Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis

8:30AM-10:30AM: Abstract Number: 0433

Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey

8:30AM-10:30AM: Abstract Number: 0415

Utility of the 22-Item Sinonasal Outcome Test Patient-Reported Outcome Instrument in ANCA-Associated Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].